Home » Newsletters » BioWorld Science

BioWorld Science

July 24, 2014

View Archived Issues

Novartis releases progress report from second quarter 2014

Vernalis and Tris Pharma achieve proof-of-concept for CCP-08

MRC Technology humanizes anti-tau monoclonal antibody for Axon Neuroscience

Epistem enters into collaborative funding agreement with GHIF for Genedrive platform and TB assay

Polaris Pharmaceuticals' ADI-PEG 20 obtains orphan drug status for mesothelioma

AOP Orphan conducting new trial in polycythemia vera

Biosceptre reports phase I results for BIL-010t in basal cell carcinoma

Advaxis and MedImmune partner on immunotherapy combination trial

Medigene's Trianta becomes project partner in German T-cell therapy collaborative research center

MODERN study of maraviroc regimen in HIV-1 infection does not meet primary endpoint

Alpharmagen describes novel alpha7-nAChR agonist

BioComo and Mie University present new hPIV2 vector-based vaccines

Puma reports topline results from phase III study of PB-272 in extended adjuvant breast cancer

Antisense Therapeutics reports data from phase I trial of ATL-1102

Bispecific, chimeric antibody-like immunoadhesin neutralizes HIV in vitro

New glycopeptide antibiotics disclosed by Chinese scientists

Vernalis and Lundbeck jointly patent novel LRRK2 inhibitors

Phase I/II safety data of a combination of a tuberculosis vaccine and antiretroviral therapy

Roche patents novel CDK8/cyclin-C inhibitors for cancer

Novel sigma1-receptor ligands disclosed by Esteve

FDA approves Ryanodex for treatment of malignant hyperthermia

Resverlogix reports MACE data in patients with diabetes treated with RVX-2018

UCB reports topline phase III results for brivaracetam in epilepsy

FDA approves Zydelig for three B-cell blood cancers

Plegridy approved in the E.U. for multiple sclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...